Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Atossa Therapeutics, Inc. ATOS
$0.70
+$0.02 (2.60%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
88598813.00000000
-
week52high
1.36
-
week52low
0.50
-
Revenue
0
-
P/E TTM
-3
-
Beta
1.16747400
-
EPS
-0.21000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Ascendiant Capital | Buy | 17 сент 2020 г. | |
| Maxim Group | Buy | Hold | 18 дек 2019 г. |
| Maxim Group | Buy | 26 янв 2018 г. | |
| Sidoti & Co. | Neutral | Buy | 07 окт 2013 г. |
| Sidoti & Co. | Buy | Buy | 15 апр 2013 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Steinhart Richard I | A | 500000 | 50000 | 13 мая 2022 г. |
| Remmel H. Lawrence | A | 50000 | 50000 | 13 мая 2022 г. |
| Chen Shu-Chih | A | 50000 | 50000 | 13 мая 2022 г. |
| WEAVER GREGORY L | A | 50000 | 50000 | 13 мая 2022 г. |
| Galli Stephen J | A | 50000 | 50000 | 13 мая 2022 г. |
| QUAY STEVEN C | A | 1900000 | 1900000 | 24 февр 2022 г. |
| Guse Kyle | A | 746667 | 746667 | 24 февр 2022 г. |
| WEAVER GREGORY L | D | 0 | 70000 | 02 июл 2021 г. |
| WEAVER GREGORY L | D | 0 | 107497 | 02 июл 2021 г. |
| WEAVER GREGORY L | D | 107497 | 57084 | 02 июл 2021 г. |
Новостная лента
Atossa Therapeutics CEO Steven Quay weighs in on US agency's revised mammogram guidelines
Proactive Investors
11 мая 2023 г. в 11:51
Atossa Therapeutics Inc (NASDAQ:ATOS) CEO Steven Quay has offered a set of recommendations to the United States Preventive Services Task Force (USPSTF) following the release of a draft report on breast cancer screening. In the report, the USPSTF calls for mammograms to begin at 40 years of age, which returns the agency to its pre-2009 stance.
Atossa Therapeutics to present insights from ongoing EVANGELINE clinical trial at ASCO Annual Meeting
Proactive Investors
09 мая 2023 г. в 10:23
Atossa Therapeutics, Inc has announced that it will present a Trial in Progress poster for the Phase 2 clinical study of (Z)-endoxifen in premenopausal women with early stage ER+ / HER2- breast cancer (EVANGELINE) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be taking place from June 2-6, 2023, in Chicago. The clinical-stage biopharmaceutical company said the session, which will be presented by Dr Matthew Goetz of the Mayo Clinic, will take place on Sunday, June 4, 2023, from 8 AM to 11 AM Central Time.
Atossa to Present a Trial in Progress Poster on its Neoadjuvant Breast Cancer Phase 2 Clinical Trial, EVANGELINE, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewsWire
09 мая 2023 г. в 09:15
SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces that a Trial in Progress poster for the Phase 2 clinical study of (Z)-endoxifen in premenopausal women with early stage ER+ / HER2- breast cancer will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023 in Chicago.
3 Best Penny Stocks Under $1 to Buy in April
InvestorPlace
11 апр 2023 г. в 20:36
As with all speculative investments, today's list of the best penny stocks under $1 should be approached with caution. Penny stocks are arguably one of the best ways to see outsized returns.
The 3 Best Biotech Stocks Under $1 to Buy for April
InvestorPlace
04 апр 2023 г. в 20:21
Typically, penny stocks are pure market wages for hardened gamblers. In fact, penny stocks are always risky — especially some of the best biotech stocks under $1 – and should oftentimes be avoided.